雅培（Abbott Laboratories）将于10月21日盘前公布Q3财报，市场预期EPS同比增8.5%至1.41美元、收入增14.2%至129.9亿美元

Abbott Laboratories ( ABT ) is scheduled to announce Q3 earnings results on October 21st, before the opening bell. Wall Street expects earnings to register an 8.5% Y/Y jump, reaching $1.41 —falling within management’s guidance range of $1.38 to $1.46—while revenue is seen advancing 14.2% Y/Y to $12.99B. Over the last 3 months, EPS estimates have seen 7 upward revisions and 11 downward moves, while revenue estimates have seen 2 upward revisions and 19 downward moves, showing a bullish sentiment among analysts. Last quarter, CEO Robert Ford said that he expects the second quarter to be majorly lifted by four areas—nutrition, electrophysiology, core lab, and cancer diagnostics. “…each of these 4 businesses is entering with a lot of momentum and line of sight to the drivers of the business,” he said. On the other hand, analysts maintain that the medical devices segment remains Abbott’s core earnings engine. According to 2025 data, medical devices accounted for ~48% of revenue and 61% of total segment profit. In H1 2026, medical device sales increased by 8.0%. “This segment, for me, is the most important argument for why Abbott can maintain a higher valuation than slower-growing healthcare businesses,” Market Edge Researcher said. Over the last 2 years, ABT has beaten EPS estimates 88% of the time and has beaten revenue estimates 50% of the time. The stock, however, has suffered in the year so far, declining nearly 16% YTD.